Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Gains from Investment Securities (2020 - 2023)

Cullinan Therapeutics (CGEM) has 4 years of Gains from Investment Securities data on record, last reported at -$4.4 million in Q4 2023.

  • For Q4 2023, Gains from Investment Securities fell 252.63% year-over-year to -$4.4 million; the TTM value through Dec 2023 reached $300000.0, down 89.61%, while the annual FY2024 figure was $10.4 million, 3366.67% up from the prior year.
  • Gains from Investment Securities reached -$4.4 million in Q4 2023 per CGEM's latest filing, down from $4.6 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $32.7 million in Q3 2022 and bottomed at -$4.4 million in Q4 2023.
  • Average Gains from Investment Securities over 4 years is $4.9 million, with a median of $2.3 million recorded in 2021.
  • The widest YoY moves for Gains from Investment Securities: up 3636.64% in 2023, down 252.63% in 2023.
  • A 4-year view of Gains from Investment Securities shows it stood at $4.6 million in 2020, then skyrocketed by 132.46% to $10.7 million in 2021, then plummeted by 73.01% to $2.9 million in 2022, then tumbled by 252.63% to -$4.4 million in 2023.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were -$4.4 million in Q4 2023, $4.6 million in Q2 2023, and $75000.0 in Q1 2023.